Literature DB >> 18279467

Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'.

Dimitrios Damaskos1, George Kolios.   

Abstract

The intestinal microflora is a large bacterial community that colonizes the gut, with a metabolic activity equal to an organ and various functions that affect the physiology and pathology of the host's mucosal immune system. Intestinal bacteria are useful in promotion of human health, but certain components of microflora, in genetically susceptible individuals, contribute to various pathological disorders, including inflammatory bowel disease. Clinical and experimental observations indicate an imbalance in protective and harmful microflora components in these disorders. Manipulation of gut flora to enhance its protective and beneficial role represents a promising field of new therapeutic strategies of inflammatory bowel disease. In this review, we discuss the implication of gut flora in the intestinal inflammation that justifies the role of probiotics and prebiotics in the prevention and treatment of inflammatory bowel disease and we address the evidence for therapeutic benefits from their use in experimental models of colitis and clinical trials.

Entities:  

Mesh:

Year:  2008        PMID: 18279467      PMCID: PMC2291386          DOI: 10.1111/j.1365-2125.2008.03096.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  187 in total

Review 1.  Probiotics in the treatment of inflammatory bowel disease.

Authors:  Kevin P Rioux; Richard N Fedorak
Journal:  J Clin Gastroenterol       Date:  2006-03       Impact factor: 3.062

2.  The effects of Lactobacillus strains and oat fiber on methotrexate-induced enterocolitis in rats.

Authors:  Y Mao; S Nobaek; B Kasravi; D Adawi; U Stenram; G Molin; B Jeppsson
Journal:  Gastroenterology       Date:  1996-08       Impact factor: 22.682

3.  Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.

Authors:  P Marteau; M Lémann; P Seksik; D Laharie; J F Colombel; Y Bouhnik; G Cadiot; J C Soulé; A Bourreille; E Metman; E Lerebours; F Carbonnel; J L Dupas; M Veyrac; B Coffin; J Moreau; V Abitbol; S Blum-Sperisen; J Y Mary
Journal:  Gut       Date:  2005-12-23       Impact factor: 23.059

4.  Protein, and dietary fiber-rich new foodstuff from brewer's spent grain increased excretion of feces and jejunum mucosal protein content in rats.

Authors:  O Kanauchi; K Agata
Journal:  Biosci Biotechnol Biochem       Date:  1997-01       Impact factor: 2.043

Review 5.  Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics.

Authors:  G R Gibson; M B Roberfroid
Journal:  J Nutr       Date:  1995-06       Impact factor: 4.798

6.  Long-term ingestion of lactosucrose increases Bifidobacterium sp. in human fecal flora.

Authors:  T Ohkusa; Y Ozaki; C Sato; K Mikuni; H Ikeda
Journal:  Digestion       Date:  1995       Impact factor: 3.216

7.  Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

Authors:  H A Malchow
Journal:  J Clin Gastroenterol       Date:  1997-12       Impact factor: 3.062

8.  Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.

Authors:  M A Zocco; L Zileri dal Verme; F Cremonini; A C Piscaglia; E C Nista; M Candelli; M Novi; D Rigante; I A Cazzato; V Ojetti; A Armuzzi; G Gasbarrini; A Gasbarrini
Journal:  Aliment Pharmacol Ther       Date:  2006-06-01       Impact factor: 8.171

9.  Effect of 4G-beta-D-galactosylsucrose (lactosucrose) on fecal microflora in patients with chronic inflammatory bowel disease.

Authors:  F Teramoto; K Rokutan; Y Kawakami; Y Fujimura; J Uchida; K Oku; M Oka; M Yoneyama
Journal:  J Gastroenterol       Date:  1996-02       Impact factor: 7.527

10.  Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group.

Authors:  W Scheppach
Journal:  Dig Dis Sci       Date:  1996-11       Impact factor: 3.199

View more
  42 in total

Review 1.  The impact of the microbiota on the pathogenesis of IBD: lessons from mouse infection models.

Authors:  Sandra Nell; Sebastian Suerbaum; Christine Josenhans
Journal:  Nat Rev Microbiol       Date:  2010-07-12       Impact factor: 60.633

2.  A natural approach to treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  Br J Clin Pharmacol       Date:  2008-04       Impact factor: 4.335

Review 3.  Current status and challenges of cytokine pharmacology.

Authors:  Z Zídek; P Anzenbacher; E Kmonícková
Journal:  Br J Pharmacol       Date:  2009-04-03       Impact factor: 8.739

Review 4.  Role of the gut microbiota in inflammatory bowel disease pathogenesis: what have we learnt in the past 10 years?

Authors:  Georgina L Hold; Megan Smith; Charlie Grange; Euan Robert Watt; Emad M El-Omar; Indrani Mukhopadhya
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

5.  Fasting-Mimicking Diet Modulates Microbiota and Promotes Intestinal Regeneration to Reduce Inflammatory Bowel Disease Pathology.

Authors:  Priya Rangan; Inyoung Choi; Min Wei; Gerardo Navarrete; Esra Guen; Sebastian Brandhorst; Nobel Enyati; Gab Pasia; Daral Maesincee; Vanessa Ocon; Maya Abdulridha; Valter D Longo
Journal:  Cell Rep       Date:  2019-03-05       Impact factor: 9.423

Review 6.  Nutraceuticals' Novel Formulations: The Good, the Bad, the Unknown and Patents Involved.

Authors:  Nada A Helal; Heba A Eassa; Ahmed M Amer; Mohamed A Eltokhy; Ivan Edafiogho; Mohamed I Nounou
Journal:  Recent Pat Drug Deliv Formul       Date:  2019

7.  Effect of Lactobacillus casei on the Production of Pro-Inflammatory Markers in Streptozotocin-Induced Diabetic Rats.

Authors:  A Zarfeshani; H Khaza'ai; R Mohd Ali; Z Hambali; K W J Wahle; M S A Mutalib
Journal:  Probiotics Antimicrob Proteins       Date:  2011-12       Impact factor: 4.609

8.  The immunomodulatory properties of viable Lactobacillus salivarius ssp. salivarius CECT5713 are not restricted to the large intestine.

Authors:  Belén Arribas; Natividad Garrido-Mesa; Laura Perán; Desirée Camuesco; Mònica Comalada; Elvira Bailón; Mónica Olivares; Jordi Xaus; Laurens Kruidenier; Ian R Sanderson; Antonio Zarzuelo; Maria Elena Rodríguez-Cabezas; Julio Gálvez
Journal:  Eur J Nutr       Date:  2011-06-19       Impact factor: 5.614

Review 9.  Microbial shift and periodontitis.

Authors:  Alex B Berezow; Richard P Darveau
Journal:  Periodontol 2000       Date:  2011-02       Impact factor: 7.589

10.  A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice.

Authors:  B Arribas; M E Rodríguez-Cabezas; D Camuesco; M Comalada; E Bailón; P Utrilla; A Nieto; A Concha; A Zarzuelo; J Gálvez
Journal:  Br J Pharmacol       Date:  2009-05-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.